IL245386A0 - A crystalline beta-lactamase inhibitor - Google Patents
A crystalline beta-lactamase inhibitorInfo
- Publication number
- IL245386A0 IL245386A0 IL245386A IL24538616A IL245386A0 IL 245386 A0 IL245386 A0 IL 245386A0 IL 245386 A IL245386 A IL 245386A IL 24538616 A IL24538616 A IL 24538616A IL 245386 A0 IL245386 A0 IL 245386A0
- Authority
- IL
- Israel
- Prior art keywords
- lactamase inhibitor
- crystalline beta
- beta
- crystalline
- lactamase
- Prior art date
Links
- 239000003781 beta lactamase inhibitor Substances 0.000 title 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 title 1
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/86—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with only atoms other than nitrogen atoms directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/87—Compounds being unsubstituted in position 3 or with substituents other than only two methyl radicals attached in position 3, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1319776.9A GB201319776D0 (en) | 2013-11-08 | 2013-11-08 | Compound |
| GBGB1408643.3A GB201408643D0 (en) | 2013-11-08 | 2014-05-15 | Compound |
| PCT/EP2014/074108 WO2015067787A1 (en) | 2013-11-08 | 2014-11-07 | Crystalline beta-lactamase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL245386A0 true IL245386A0 (en) | 2016-06-30 |
Family
ID=49818360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL245386A IL245386A0 (en) | 2013-11-08 | 2016-05-02 | A crystalline beta-lactamase inhibitor |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20160289245A1 (OSRAM) |
| EP (1) | EP3066103A1 (OSRAM) |
| JP (2) | JP7045795B2 (OSRAM) |
| KR (1) | KR20160081964A (OSRAM) |
| CN (1) | CN105873935B (OSRAM) |
| AU (1) | AU2014345507B2 (OSRAM) |
| CA (1) | CA2929199C (OSRAM) |
| CL (1) | CL2016001097A1 (OSRAM) |
| EA (1) | EA031348B1 (OSRAM) |
| GB (2) | GB201319776D0 (OSRAM) |
| IL (1) | IL245386A0 (OSRAM) |
| MX (1) | MX2016005869A (OSRAM) |
| PE (1) | PE20160890A1 (OSRAM) |
| WO (1) | WO2015067787A1 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201319776D0 (en) * | 2013-11-08 | 2013-12-25 | Allecra Therapeutics Sas | Compound |
| WO2026086730A1 (zh) * | 2024-10-21 | 2026-04-30 | 齐鲁制药有限公司 | 恩美他唑巴坦的晶型及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4562073A (en) * | 1982-12-24 | 1985-12-31 | Taiho Pharmaceutical Company Limited | Penicillin derivatives |
| US6156745A (en) * | 1997-12-29 | 2000-12-05 | Research Corporation Technologies, Inc. | 2β-substituted-6-alkylidene penicillanic acid derivatives as β-lactamase inhibitors |
| US7273935B2 (en) * | 2003-08-21 | 2007-09-25 | Orchid Chemicals & Pharmaceuticals, Ltd. | Process for the preparation of 3-methylcepham derivatives |
| US7417143B2 (en) * | 2004-04-07 | 2008-08-26 | Orchid Chemicals & Pharmaceuticals Limited | Process for the preparation of Tazobactam in pure form |
| US7687488B2 (en) * | 2006-07-12 | 2010-03-30 | Orchid Chemicals & Pharmaceuticals Ltd. | 2-substituted methyl penam derivatives |
| NZ610247A (en) * | 2010-11-25 | 2014-09-26 | Allecra Therapeutics Gmbh | Β-lactamase inhibitors and their use |
| EP2847205A4 (en) * | 2012-05-07 | 2016-01-20 | Univ California | NOVEL OXYSTEROL ANALOGUE OXY149 FOR THE INDUCTION OF OSTEOGENESIS AND HEDGEHOG SIGNAL PATH AND THE INHIBITION OF ADIPOGENESIS |
| US9683009B2 (en) * | 2013-05-02 | 2017-06-20 | The Regents Of The University Of California | Bone-selective osteogenic oxysterol-bone targeting agents |
| GB201319776D0 (en) | 2013-11-08 | 2013-12-25 | Allecra Therapeutics Sas | Compound |
| GB201408649D0 (en) * | 2014-05-15 | 2014-07-02 | Allecra Therapeutics Sas | Method |
| KR20170101940A (ko) * | 2014-12-09 | 2017-09-06 | 워쏘우 오르쏘페딕 인코포레이티드 | 스테롤 관련 화합물 및 방법 |
-
2013
- 2013-11-08 GB GBGB1319776.9A patent/GB201319776D0/en not_active Ceased
-
2014
- 2014-05-15 GB GBGB1408643.3A patent/GB201408643D0/en not_active Ceased
- 2014-11-07 US US15/035,176 patent/US20160289245A1/en not_active Abandoned
- 2014-11-07 KR KR1020167014701A patent/KR20160081964A/ko not_active Withdrawn
- 2014-11-07 EA EA201690963A patent/EA031348B1/ru not_active IP Right Cessation
- 2014-11-07 JP JP2016527458A patent/JP7045795B2/ja active Active
- 2014-11-07 CA CA2929199A patent/CA2929199C/en active Active
- 2014-11-07 AU AU2014345507A patent/AU2014345507B2/en active Active
- 2014-11-07 WO PCT/EP2014/074108 patent/WO2015067787A1/en not_active Ceased
- 2014-11-07 EP EP14799382.8A patent/EP3066103A1/en not_active Withdrawn
- 2014-11-07 MX MX2016005869A patent/MX2016005869A/es unknown
- 2014-11-07 PE PE2016000598A patent/PE20160890A1/es not_active Application Discontinuation
- 2014-11-07 CN CN201480071497.4A patent/CN105873935B/zh active Active
-
2016
- 2016-05-02 IL IL245386A patent/IL245386A0/en unknown
- 2016-05-06 CL CL2016001097A patent/CL2016001097A1/es unknown
-
2018
- 2018-10-31 US US16/177,406 patent/US11124526B2/en active Active
-
2021
- 2021-03-26 JP JP2021052653A patent/JP7346485B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3066103A1 (en) | 2016-09-14 |
| GB201319776D0 (en) | 2013-12-25 |
| CA2929199A1 (en) | 2015-05-14 |
| GB201408643D0 (en) | 2014-07-02 |
| US20190071456A1 (en) | 2019-03-07 |
| JP7045795B2 (ja) | 2022-04-01 |
| CN105873935B (zh) | 2019-03-19 |
| CA2929199C (en) | 2023-01-03 |
| CL2016001097A1 (es) | 2016-12-02 |
| AU2014345507A1 (en) | 2016-05-19 |
| WO2015067787A1 (en) | 2015-05-14 |
| JP2016535054A (ja) | 2016-11-10 |
| US20160289245A1 (en) | 2016-10-06 |
| AU2014345507B2 (en) | 2018-11-22 |
| JP2021102642A (ja) | 2021-07-15 |
| EA031348B1 (ru) | 2018-12-28 |
| JP7346485B2 (ja) | 2023-09-19 |
| KR20160081964A (ko) | 2016-07-08 |
| PE20160890A1 (es) | 2016-08-25 |
| CN105873935A (zh) | 2016-08-17 |
| MX2016005869A (es) | 2017-01-05 |
| US11124526B2 (en) | 2021-09-21 |
| EA201690963A1 (ru) | 2016-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201800913B (en) | Syk inhibitors | |
| EP2970340A4 (en) | BETA-Lactamase INHIBITORS | |
| EP2943204A4 (en) | BETA-Lactamase INHIBITORS | |
| IL243202A0 (en) | Crystalline inhibitors of bromine sites | |
| IL243578A0 (en) | syk inhibitors | |
| ZA201504200B (en) | Beta-lactamase inhibitors | |
| IL239827A0 (en) | Deoxyuridine triphosphatase inhibitors | |
| ZA201506156B (en) | Novel inhibitors | |
| GB201314578D0 (en) | Bicyclic inhibitors | |
| GB201317609D0 (en) | Inhibitor compounds | |
| SG11201509650YA (en) | Slc2a transporter inhibitors | |
| GB201313664D0 (en) | Bcl-3 inhibitors | |
| GB201319776D0 (en) | Compound | |
| EP2945930A4 (en) | Novel ddp-iv inhibitors | |
| GB201300903D0 (en) | Crystalline Form | |
| HK1228402A (en) | Crystalline beta-lactamase inhibitor | |
| GB201321328D0 (en) | Inhibitor compounds | |
| GB201305503D0 (en) | Inhibitor | |
| GB201301842D0 (en) | Beta-Lactam Compounds | |
| HK1225374A1 (en) | Syk inhibitors |